BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:  Tuesday, August 6, 2024
Time: 8:30 AM Eastern Time
United States: 1-877-300-8521
International: 1-412-317-6026
Israel: 1-80-921-2373
Conference ID: 10190847
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1679332&tp_key=1f7beb24a2
   

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts: 
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com

Staff

Recent Posts

Community Hospital of Anaconda Notifies Individuals of Data Security Incident

ANACONDA, Mont., May 19, 2025 /PRNewswire/ -- Community Hospital of Anaconda ("CHA") is providing notice…

3 hours ago

Teal Health Announces Publication of SELF-CERV Study Results in JAMA Network Open Following FDA Approval of Teal Wand™ for At-Home HPV Screening

SAN FRANCISCO, May 19, 2025 /PRNewswire/ -- Following its recent FDA approval, Teal Health® announced the…

3 hours ago

BI2 Technologies and Support Our Sheriffs Foundation partner with SingleCare to create Sheriff Rx

Free program will provide access to affordable medications to Sheriffs' employees across the nation PLYMOUTH,…

3 hours ago

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

Collaboration Blends Advanced Cloud Technologies, Open-Source Collaboration, and Data Science Integration to support UCB's development pipeline…

3 hours ago

Persist AI Launches Cloud Lab to Accelerate Pharmaceutical Formulation Development, Raises $12M Series A Funding

AI-driven robotics platform reduces drug formulation development time from years to months SACRAMENTO, Calif., May…

3 hours ago

United Imaging Emphasizes Differentiated Technology at ISMRM 2025

Among the highlights were a completely unique whole-body 8 ch-parallel transmit coil on the 5T…

3 hours ago